Did you lose money on investments in Axsome Therapeutics? If so, please visit Axsome Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter.
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) has been assigned a consensus rating of “Buy” from the twelve ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to […]
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) – SVB Leerink cut their Q2 2022 earnings estimates for shares of Axsome Therapeutics in a report released on Thursday, April 21st. SVB Leerink analyst M. Goodman now expects that the company will earn ($1.09) per share for the quarter, down from their prior estimate of ($1.05). SVB […]
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) – Analysts at William Blair boosted their Q1 2023 EPS estimates for Axsome Therapeutics in a note issued to investors on Wednesday, April 20th. William Blair analyst M. Minter now anticipates that the company will earn ($0.20) per share for the quarter, up from their prior estimate of […]
Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) have been given an average recommendation of “Buy” by the twelve brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and nine have given a buy recommendation […]